Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pseudomonas Clear all
Completed Phase 1Phase 2 Interventional Results available

CYstic Fibrosis bacterioPHage Study at Yale (CYPHY)

NCT04684641
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Standard Dose YPT-01, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Jul 22, 2026, 11:13 PM EDT
Completed Not applicable Interventional

Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)

NCT00153634
View directory record Official record
Conditions
Cystic Fibrosis, Chronic Bronchitis
Interventions
IV amikacin, PO azithromycin, IV ceftazidime, PO ciprofloxacin, IV meropenem, IV piperacillin-tazobactam, IV ticarcillin-clavulanate, IV tobramycin
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
14 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2008 · Synced Jul 22, 2026, 11:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Reducing ESKAPE Transmission in the Operating Room

NCT06274918
View directory record Official record
Conditions
Surgical Procedure, Unspecified
Interventions
Personalized Body-Worn Alcohol Dispenser
Device
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Jul 22, 2026, 11:13 PM EDT
Completed No phase listed Observational

Clinical and Microbiological Outcomes of Infections Due to Carbapenem-Resistant Gram-Negative Bacteria

NCT01041716
View directory record Official record
Conditions
Drug Resistance, Microbial
Interventions
None - Observational study
Other
Lead sponsor
Maimonides Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Jul 22, 2026, 11:13 PM EDT
Completed No phase listed Observational

Detecting Infections Rapidly and Easily for Bacteremia Trial (DIREBT)

NCT01919762
View directory record Official record
Conditions
Bacteremia
Interventions
Not listed
Lead sponsor
T2 Biosystems
Industry
Eligibility
18 Years to 95 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 27, 2015 · Synced Jul 22, 2026, 11:13 PM EDT
Terminated Phase 4 Interventional Results available

Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis

NCT01694069
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Piperacillin-tazobactam combination product
Drug
Lead sponsor
West Virginia University
Other
Eligibility
8 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Jul 22, 2026, 11:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa

NCT05453578
View directory record Official record
Conditions
Bacterial Disease Carrier, Cystic Fibrosis
Interventions
Placebo, WRAIR-PAM-CF1
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
19
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 22, 2026, 11:13 PM EDT
Completed No phase listed Observational

Tissue Collection From People With Cystic Fibrosis

NCT00015756
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
9 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
2
States / cities
Bethesda, Maryland • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 11:13 PM EDT
Completed No phase listed Observational

Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs

NCT02449031
View directory record Official record
Conditions
Pseudomonas Aeruginosa in Cystic Fibrosis
Interventions
TOBI® PODHALER®, TOBI®, Bethkis®, Cayston®
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
6 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
47
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Bellflower, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Jul 22, 2026, 11:13 PM EDT
Terminated Phase 3 Interventional

Pivotal Study in Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas

NCT03582007
View directory record Official record
Conditions
Pneumonia
Interventions
Murepavadin, One anti-pseudomonal antibiotic
Drug
Lead sponsor
Polyphor Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Iowa City, Iowa • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Jul 22, 2026, 11:13 PM EDT
Completed Phase 4 Interventional Results available

Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa

NCT00431964
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
azithromycin 250 mg tablets, placebo tablets
Drug
Lead sponsor
CF Therapeutics Development Network Coordinating Center
Network
Eligibility
6 Years to 18 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
31
States / cities
Phoenix, Arizona • Hartford, Connecticut • Atlanta, Georgia + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Jul 22, 2026, 11:13 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment

NCT01695343
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
KB001-A, Placebo Comparator
Biological · Drug
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
12 Years to 50 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
58
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Jul 22, 2026, 11:13 PM EDT
Recruiting Phase 2 Interventional

Study With Phage for CF Subjects With Pseudomonas Lung Infection

NCT06998043
View directory record Official record
Conditions
Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF)
Interventions
BX004, Placebo
Biological · Other
Lead sponsor
BiomX Ltd
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Jul 22, 2026, 11:13 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects

NCT03669614
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled AR-501, Inhaled Placebo
Drug
Lead sponsor
Aridis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
25
States / cities
Tucson, Arizona • Long Beach, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Jul 22, 2026, 11:13 PM EDT
Completed No phase listed Observational

Multi-Drug Resistant Organism Network

NCT03646227
View directory record Official record
Conditions
Infections Resistant to Multiple Drugs, Bacterial Infections
Interventions
Standard of Care
Other
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
6,496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2023 · Synced Jul 22, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

NCT00112359
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZLI 75 mg three times a day (TID), Placebo three times a day (TID)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
40
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2011 · Synced Jul 22, 2026, 11:13 PM EDT
Completed Phase 3 Interventional

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)

NCT01515007
View directory record Official record
Conditions
Non Cystic Fibrosis Bronchiectasis
Interventions
Ciprofloxacin dispersion for inhalation, Placebo
Drug
Lead sponsor
Aradigm Corporation
Industry
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
30
States / cities
Peoria, Arizona • Phoenix, Arizona • Downey, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Jul 22, 2026, 11:13 PM EDT
Terminated Phase 4 Interventional Results available

Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation

NCT04673175
View directory record Official record
Conditions
Pneumonia, Hematologic Malignancy, Pseudomonas Aeruginosa Infection, Bacteremia, Hematopoietic Stem Cell Transplant (HSCT)
Interventions
Ceftolozane / Tazobactam Injection
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Jul 22, 2026, 11:13 PM EDT
Not listed Not applicable Interventional

Reducing Intraoperative ESKAPE Transmission Through Use of a Personal Hand Hygiene System

NCT04900298
View directory record Official record
Conditions
Surgical Wound Infection, Cross Infection
Interventions
SafeHaven Automated Hand Hygiene Device
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Jul 22, 2026, 11:13 PM EDT
Completed Phase 4 Interventional Results available

Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children

NCT01429259
View directory record Official record
Conditions
Cystic Fibrosis, Pneumonia, Pseudomonas Aeruginosa Infection
Interventions
meropenem
Drug
Lead sponsor
Joseph Kuti
Other
Eligibility
6 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Hartford, Connecticut • Indianapolis, Indiana • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Jul 22, 2026, 11:13 PM EDT
Completed Not applicable Interventional

Benefits and Risks of Newborn Screening for Cystic Fibrosis

NCT00014950
View directory record Official record
Conditions
Cystic Fibrosis, Lung Disease, Pseudomonas Infections
Interventions
CF newborn screening
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
1 Month to 21 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Jul 22, 2026, 11:13 PM EDT
Completed Phase 4 Interventional Results available

Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients

NCT02421120
View directory record Official record
Conditions
Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation, Pseudomonas Aeruginosa Infection
Interventions
Ceftolozane/Tazobactam
Drug
Lead sponsor
Joseph L. Kuti, PharmD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Hartford, Connecticut • Indianapolis, Indiana • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Jul 22, 2026, 11:13 PM EDT
Terminated Phase 3 Interventional

Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa

NCT03409679
View directory record Official record
Conditions
Pneumonia
Interventions
Murepavadin, Two anti-pseudomonal antibiotics
Drug
Lead sponsor
Polyphor Ltd.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Chicago, Illinois • Springfield, Missouri • Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Jul 22, 2026, 11:13 PM EDT
Withdrawn No phase listed Observational

Microbiota of the Respiratory Flora in Children With Cystic Fibrosis During the First Year of Life

NCT00977158
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Throat Swab
Procedure
Lead sponsor
Tufts Medical Center
Other
Eligibility
1 Day to 3 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Jul 22, 2026, 11:13 PM EDT